Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
Endocrinology and Metabolism
;
: 202-205, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-55017
ABSTRACT
Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Servicio de Urgencia en Hospital
/
Estupor
/
Hemangiopericitoma
/
Hipoglucemia
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Endocrinology and Metabolism
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS